Kidney Week

Abstract: FR-PO267

Prevalence of Cisplatin-Induced Nephrotoxicity in an Inner-City Population in the Bronx, New York

Session Information

• Onconephrology: From AKI to CKD and Everything in Between
  November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Onconephrology

• 1700 Onconephrology

Authors

• Hammami, M Bakri, New York City Health and Hospitals Jacobi, Bronx, New York, United States

M Bakri Hammami,

• Gudino, Paola, New York City Health and Hospitals Jacobi, Bronx, New York, United States

Paola Gudino,

• Rodriguez Salazar, Juan Diego, New York City Health and Hospitals Jacobi, Bronx, New York, United States

Juan Diego Rodriguez Salazar,

• Vegivinti, Charan Thej Reddy, New York City Health and Hospitals Jacobi, Bronx, New York, United States

Charan Thej Reddy Vegivinti,

• Acharya, Anjali, New York City Health and Hospitals Jacobi, Bronx, New York, United States

Anjali Acharya,

Background

Cisplatin is a commonly used chemotherapeutic agent with known nephrotoxicity. Studies evaluating its nephrotoxicity in minorities are limited. We assessed the incidence of kidney injury among our adult patients receiving cisplatin.

Methods

Retrospective review of records for adult patients receiving cisplatin from Jan 2021 to Jan 2023 was conducted. Serum Creatinine (SCr) and estimated glomerular filtration rate (eGFR) were obtained at baseline and within 30 days after cycles 1, 2, and 3 of Cisplatin. KDIGO definition was used to diagnose AKI.

Results

Of the 47 patients included in the analysis, 51.1% were male (n=24), median (range) age was 58 years (19-78). 42.6% were Black (n=20), 21.3% White (n=10) and others consisting of Pacific Islanders, American Indians, and Asians represented 36.2% (n=17). 80% of whites were Hispanic. The median number of cisplatin cycles was 4 (range: 1-11). Median baseline eGFR and SCr was 99.7ml/min and 0.80 g/dl, respectively. Blacks had a mean baseline GFR of 86.1ml/min, while non-Blacks had a mean of 100.86 ml/min (t=2.223, p=0.031). The median eGFR and SCr at the last follow-up after cisplatin was 77.80 ml/min and 0.99 g/dl, respectively. 10.6% of the patients developed AKI after the first dose of Cisplatin. There was no statistically significant correlation between race, sex, BMI or the use of immune checkpoint inhibitors and development of AKI. Repeated measures ANOVA test was conducted to evaluate the change in patients’ creatinine when measured before cisplatin, after 1^st, 2^nd and 3^rd cycle. The results indicated a statistically significant rise in creatinine level following cisplatin therapy [Wilks’ Lambda = 0.003, F (1, 26) = 13.7, η² = 0.44].

Conclusion

Our retrospective study in a minority based, low socioeconomic status adult population highlights the progressive risk of kidney injury following each cycle of cisplatin therapy, indicating risk for chronic dose-dependent cisplatin-induced nephrotoxicity. Patients from low socioeconomic backgrounds and minority populations may be at higher risk for renal dysfunction and progression to CKD. Further prospective studies targeting this specific population are warranted to validate these findings and develop tailored interventions to reduce cisplatin-induced nephrotoxicity.